Nora Möhn

MD, neurologist in training and clinician scientist at Hannover Medical School. Interested in neuroimmunology and neurooncology 🧠🥼🔬 @practis_mhh

[Nora Möhn @MohnNora]

Excited about our latest publication on DIAVIS T cells for treating PML.
Onward to more advancements! #PML #Innovation #DIAVISTcells #Research

[JAMA Neurology @JAMANeuro]

Case series of DIAVIS T-cell therapy in progressive multifocal leukoencephalopathy provides first class IV evidence suggesting efficacy to reduce mortality and improve functional outcome. https://t.co/rjUOYdHwYj

[Nat Rev Neurology @NatRevNeurol]

CAR T therapy for multiple sclerosis enters US trials for first time https://t.co/uwKD00W5vc

[Ramona Schmitt @_Ramona_Schmitt]

Sehr interessanter Vortrag von @MohnNora in einer tollen Session #interdisziplinär! #DGKHerztage @YoungDgk

[Wolfgang Wick 🇪🇺 @wick_wolfgang]

Terrific news for patients with IDH mutated gliomas. Finally, we have a truly molecular targeted therapy in Neurooncology based on excellent basic research and clinical translation.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/rof5qWDIIQ

[Nora Möhn @MohnNora]

#neurowoche2022 it was a pleasure!
Besides the contact to many great colleagues and new research ideas, the awarding of one of the poster prizes for our work on treatment of PML with virusspecific T cells was a true highlight! See you next year #DGN
@PRACTIS_MHH @NeuroSkripuletz

[Nora Möhn @MohnNora]

https://t.co/pqGOjYT9oU #mdpibrainsci via @BrainSci_MDPI Congrats to my colleague Felix Konen: Interesting work on the influence of the ventricular-lumbar gradient on CSF analysis.
#neuroscience #practismhh @PRACTIS_MHH

[Nora Möhn @MohnNora]

Proud to have such a great cooperation with my hematological colleagues and friends!!

https://t.co/ThoMP0iuhG

[Nora Möhn @MohnNora]

@gerritgrosse @StrokeAHA_ASA Great job! 🤗👍🏻

[Nora Möhn @MohnNora]

Happy to share our results on kynurenine as a pot. biomarker for differentiation between NMDARE and HSE #MHH #clinicianscientist @PRACTIS_MHH https://t.co/65mFOQT7nS

[Nora Möhn @MohnNora]

@AO_Neurology @PRACTIS_MHH So toll Alma ♥️♥️

[PRACTIS @PRACTIS_MHH]

Why should you become a Clinician Scientist in one of MHH's programms?

More informations: https://t.co/ysWqqONGkx

#Vimeo https://t.co/VEsFdO4iH7

[PRACTIS @PRACTIS_MHH]

Congratulations to @PRACTIS_MHH supported @MohnNora on winning the 2021 DGLN poster award for her project
"Differentiation between viral and autoimmune CNS inflammation using the kynurenine signaling pathway".

https://t.co/B7FzVRzpqc

[Nora Möhn @MohnNora]

Happy to have a new, potentially effective treatment option for PML available. For more information, visit website below. CurePML.
https://t.co/Rftzc1mdHo

[PRACTIS @PRACTIS_MHH]

Congratulations to all authors! Hopfner, @PRACTIS_MHH supported @MohnNora and Eiz-Vesper et al. with @NeuroSkripuletz as the last author analyzed the effects of allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients with PML https://t.co/qX0XsLgynY

[PRACTIS @PRACTIS_MHH]

@PRACTIS_MHH supported #ClinicianScientist @MohnNora et al. evaluated PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Congrats! @SAGEJournals https://t.co/PhsrmtmfQ5

[Thomas Skripuletz @NeuroSkripuletz]

An overview of published cases shows that #immunosuppressive therapy in #MultipleSclerosis does not appear to be a substantial risk factor for severe #COVID19 course.

https://t.co/Eohb9dKcaM